Potential New Treatment for Alpha-1 Antitrypsin Deficiency Trial Objective Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD. Enrollment Active Clinical Trials Closed to Recruitment Who Can Participate People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate. Age: 18-80 Gender: Any Gender Estimated Time Commitment Not Specified × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Kristina Eliopoulos 303.270.2622 Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors National Institutes of Health, University of Alabama at Birmingham Principal Investigators Robert Sandhaus, MD, PhD, FCCP + × Robert Sandhaus, MD, PhD, FCCP Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Make an Appoinment Co-Investigators Karina Serban, MD + × Karina Serban, MD Assistant Professor Department of Medicine Division of Pulmonary, Critical Care & Sleep Medicine View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment
Trial Objective Researchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.